Ocuphire Pharma
study design assessed alone efficacy ace | Ocuphire Pharma
Company
Deck Type
Deck date
January 2022
Slide
90 of 114
Related slides by other companies
ATAI
Investor Presentation
January 2023
phase proof of concept trial design all subjects tid tid placebo trial status recruitment ongoing results anticipated randomized week study of and in patients with | ATAI
ATAI
Investor Presentation
February 2023
phase proof of concept trial design all subjects tid tid placebo trial status recruitment ongoing results anticipated randomized week study of and in patients with | ATAI
OKYO Pharma
Results
June 2023
phase trial design rota | OKYO Pharma
NeuroSense Therapeutics
Investor Presentation
January 2024
slowed the loss of physical functions placebo a | NeuroSense Therapeutics
Other recent decks by Ocuphire Pharma
See all presentations (10 decks)
Investor Presentation
November 2023
Investor Presentation
August 2023
Investor Presentation
May 2023
Results
January 2023
Search Thousands of Presentations by World Leading Companies
Trending:
Addressable Market
Ecosystem
Beauty Market
WACC
NFT
Management Team
Investment Highlights